NZ744323A - Compositions comprising 15-hepe and methods of using the same - Google Patents

Compositions comprising 15-hepe and methods of using the same

Info

Publication number
NZ744323A
NZ744323A NZ744323A NZ74432316A NZ744323A NZ 744323 A NZ744323 A NZ 744323A NZ 744323 A NZ744323 A NZ 744323A NZ 74432316 A NZ74432316 A NZ 74432316A NZ 744323 A NZ744323 A NZ 744323A
Authority
NZ
New Zealand
Prior art keywords
hepe
compositions
methods
same
subject
Prior art date
Application number
NZ744323A
Other languages
English (en)
Inventor
David Coughlan
John Climax
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Priority to NZ766360A priority Critical patent/NZ766360B2/en
Publication of NZ744323A publication Critical patent/NZ744323A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ744323A 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same NZ744323A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ766360A NZ766360B2 (en) 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Publications (1)

Publication Number Publication Date
NZ744323A true NZ744323A (en) 2020-08-28

Family

ID=57995240

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ744323A NZ744323A (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Country Status (18)

Country Link
US (5) US9855238B2 (OSRAM)
EP (2) EP3389647B1 (OSRAM)
JP (4) JP2018537513A (OSRAM)
KR (6) KR20180094516A (OSRAM)
CN (2) CN108697680A (OSRAM)
AR (1) AR107143A1 (OSRAM)
AU (4) AU2016370626B2 (OSRAM)
BR (1) BR122023026625A2 (OSRAM)
CA (2) CA3008774C (OSRAM)
ES (1) ES2948444T3 (OSRAM)
IL (3) IL318963A (OSRAM)
MX (2) MX394051B (OSRAM)
NZ (1) NZ744323A (OSRAM)
PH (1) PH12018501279A1 (OSRAM)
RU (2) RU2020137883A (OSRAM)
SG (1) SG11201805149XA (OSRAM)
WO (1) WO2017103671A1 (OSRAM)
ZA (2) ZA201804779B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
CA3008774C (en) 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN1202068C (zh) 2000-02-16 2005-05-18 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CZ299784B6 (cs) 2001-05-30 2008-11-26 Laxdale Limited Lécivo obsahující EPA a ubichinon pro lécení non-Hodgkinova lymfomu, psychiatrických a neurologických chorob
AU2003284617A1 (en) 2002-11-22 2004-06-18 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
WO2006007510A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2762939C (en) * 2009-05-22 2017-07-18 Mochida Phamaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2014530841A (ja) 2011-10-19 2014-11-20 ディグニティサイエンシスリミテッド Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP3072510B1 (en) * 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
EP4205546A1 (en) * 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN111888343A (zh) * 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018502163A (ja) 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
CA3008774C (en) 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Also Published As

Publication number Publication date
ES2948444T3 (es) 2023-09-12
RU2018126361A (ru) 2020-01-22
IL259846A (en) 2018-07-31
JP2021178840A (ja) 2021-11-18
US20250281442A1 (en) 2025-09-11
EP3389647B1 (en) 2023-04-05
NZ766360A (en) 2025-05-30
NZ783466A (en) 2025-05-30
CN108697680A (zh) 2018-10-23
US20180104207A1 (en) 2018-04-19
CA3008774C (en) 2021-10-12
PH12018501279A1 (en) 2019-01-28
AU2020267224A1 (en) 2020-12-10
EP3389647A1 (en) 2018-10-24
ZA202104969B (en) 2023-01-25
CN113230244A (zh) 2021-08-10
WO2017103671A1 (en) 2017-06-22
AU2016370626A1 (en) 2018-08-02
ZA201804779B (en) 2019-09-25
SG11201805149XA (en) 2018-07-30
KR20220038818A (ko) 2022-03-29
AU2020267224B2 (en) 2022-09-29
EP4218736A3 (en) 2023-10-18
AU2025201593A1 (en) 2025-03-20
AR107143A1 (es) 2018-03-28
US20170172965A1 (en) 2017-06-22
MX379262B (es) 2025-03-10
CA3008774A1 (en) 2017-06-22
KR20250130433A (ko) 2025-09-01
IL294736A (en) 2022-09-01
CA3129008A1 (en) 2017-06-22
KR20240052856A (ko) 2024-04-23
RU2018126361A3 (OSRAM) 2020-01-22
BR122023026625A2 (pt) 2024-01-16
EP4218736A2 (en) 2023-08-02
JP2020063259A (ja) 2020-04-23
US20190224154A1 (en) 2019-07-25
RU2737089C2 (ru) 2020-11-24
RU2020137883A (ru) 2020-12-03
KR20230047501A (ko) 2023-04-07
MX2021000773A (es) 2022-07-19
BR112018012313A2 (pt) 2018-12-04
AU2022291628A1 (en) 2023-02-02
KR20200055154A (ko) 2020-05-20
US9855238B2 (en) 2018-01-02
JP2018537513A (ja) 2018-12-20
MX2018007390A (es) 2018-11-09
US12274685B2 (en) 2025-04-15
MX394051B (es) 2025-03-24
JP2023153863A (ja) 2023-10-18
KR20180094516A (ko) 2018-08-23
US20230106655A1 (en) 2023-04-06
US10231945B2 (en) 2019-03-19
IL318963A (en) 2025-04-01
AU2022291628B2 (en) 2025-04-03
AU2016370626B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12016500024A1 (en) Bromodomain inhibitor
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ZA201606320B (en) Human plasma kallikrein inhibitors
NZ720478A (en) Autotaxin inhibitor compounds
IN2015DN01156A (OSRAM)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
IN2013MU03583A (OSRAM)
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
HK1217092A1 (zh) 治疗性化合物及其用途
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2022 BY CPA GLOBAL

Effective date: 20211104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2023 BY CPA GLOBAL

Effective date: 20221224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2024 BY CPA GLOBAL

Effective date: 20231102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2025 BY CPAGLOBAL

Effective date: 20250531